Company news

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A (SSE:600276) news

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Oct 8, 2026: Jiangsu Hengrui Pharmaceuticals : Hengrui Pharma Announces EMA…

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A (SSE:600276) news

Press releases & updates

Jiangsu Hengrui Pharmaceuticals : Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer

Jiangsu Hengrui Pharmaceuticals : Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Initial Repurchase of the Company's A-Shares

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Notice on Convening the 1st Extraordinary General Meeting in 2026

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning A-Share Repurchase

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Implementation Result of Shares Repurchase and Share Changes

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Orphan Drug Designation from the US FDA

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Drug Registration Approval

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in A-share Repurchase

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Notice of Approval for Drug Clinical Trial

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Inclusion of Drug in Breakthrough Therapy Designation List

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Inclusion of Key Pharmaceutical Products of the Company in the National Essential Medicines List

Jiangsu Hengrui Pharmaceuticals : Hengrui Pharma Announces Positive Topline Data from Two Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Announcement on Obtaining Drug Registration Approval

Announcement on Withdrawal of Drug Registration Application

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA

Announcement on Obtaining Notice of Approval for Drug Clinical Trial

Announcement on Progress in A-share Repurchase

Announcement on Convening the Q1 2026 Performance Briefing

Announcement on Implementation of Dividend Distribution for 2025

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

Announcement on Inclusion of Drug in Breakthrough Therapy Designation List

Announcement on Resolutions of the 1st Meeting of the 10th Board of Directors

Announcement on Completion of Unlocking the Lockup Period of Employee Stock Ownership Plan

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Announcement on Convening the 2025 Annual Performance and Cash Dividend Briefing

Hengrui Pharma Announces Strong 2025 Annual Results

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization

Announcement on Election of Employee Representative Directors for the 10th Board of Directors

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Announcement on FDA Acceptance for Review of the Resubmitted Biologics License Application for Camrelizumab for Injection

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Resolutions of the 15th Meeting of the 9th Board of Supervisors

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer